Trial Profile
Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Therapeutic Use
- 08 Nov 2019 Status changed from completed to discontinued.
- 08 Nov 2019 Status changed from completed to discontinued.
- 19 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.